曲妥珠单抗联合蒽环类脂质体治疗HER2阳性转移性乳腺癌(附1例报道并文献复习)  

Trastuzumab Combined with Liposomal Anthracycline Treatment of HER2 Positive Metastatic Breast Cancer (A Case Report and Review)

作　　者：张还珠[1] 刘芯[1] 李莹[1] 郜靓[1] 黄振倩[1] 谭获[1] 

机构地区：[1]广州医学院第一附属医院肿瘤血液中心,广东广州510230

出　　处：《广州医学院学报》2009年第3期49-53,共5页Academic Journal of Guangzhou Medical College

摘　　要：目的:评价曲妥珠单抗联合蒽环类脂质体治疗HER2阳性转移性乳腺癌的疗效与心脏毒性。方法:1例HER2阳性转移性乳腺癌患者,予"赫赛汀+楷莱+环磷酰胺"方案化疗4程,序贯"泰素+赫赛汀"方案化疗4程,赫赛汀4 mg/kg第1周,后每周2 mg/kg治疗1年。结果:患者化疗4程后LVEF下降4%,全部化疗结束后疗效评价为完全缓解,化疗过程及随访未见心脏毒性。结论:曲妥珠单抗联合蒽环类脂质体治疗HER2阳性转移性乳腺癌是一个疗效显著,心脏毒性低的方案。Objective： To evaluate the efficacy and cardiotoxicity of trastuzumab combined with liposomal anthracycline treatment of HER2 positive metastatic breast cancer. Methods： 1 case breast cancer with HER2 positive metastatic, she was received 4 cycles chemotherapy of ＂Caelys ＋ cyclophosphamide ＋ herceptin＂, followed by 4 cycles chemotherapy of ＂Taxol ＋ herceptin＂, trastuzumab was administered 4 mg/kg at the first week followed by 2 mg/kg weekly for 1 year. Results： The patient experienced a LVEF decline 4% after four cycles of chemotherapy. Therapeutic effect was complete response after finished total chemotherapy. There was not cardiotoxicity in the course of chemotherapy and follow-up times. Conclusions： Liposomal anthracycline combined with trastuzumab is a regimen of significantly high efficacy and less cardiotoxicity in HER2 positive metastatic breast cancer.

关 键 词：乳腺癌 蒽环类脂质体 曲妥珠单抗 人类表皮生长因子受体 

分 类 号：R737.9[医药卫生—肿瘤]